Satoshi Kamio

Satoshi Kamio

Auto-generated profile, based on publicly available information

Satoshi Kamio

Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Radiology Case Reports
Verified
Journal Article
Open access
SKSatoshi Kamio
Satoshi Kamio
MAManabu Arai
Manabu Arai
SMShunsuke Matsumoto
Shunsuke Matsumoto
MSMasato Saito
Masato Saito
NANaofumi Asano
Naofumi Asano
RNRobert Nakayama
Robert Nakayama
Brodie's abscess is a relatively rare subacute form of osteomyelitis. Early diagnosis is challenging because of its insidious onset and vague symptoms. Magnetic resonance imaging is helpful in the diagnosis of Brodie's abscess; however, to date, no study has described the imaging findings of this disease in the early stage. Here, we present the case of a 14 year-old boy with Brodie's abscess in the proximal tibia. The lesion initially presented as a bone marrow edema in the proximal metaphysis of the left tibia on MRI and was misinterpreted as a bone bruise. Further radiological examination was performed 1 month later; this revealed the formation of an abscess cavity, which suggested Brodie's abscess. The patient was referred to our hospital and underwent curettage and debridement, which led to the definitive diagnosis of Brodie's abscess on histopathological findings and bacterial culture. On careful retrospective evaluation, the initial radiological findings suggested a microabscess on the metaphyseal side of the growth plate and bone marrow edema spreading from the lesion to the epiphysis. These radiological changes could be reliable evidence proving that the metaphyseal side of the growth plate is the origin of Brodie's abscess. Moreover, bone marrow edema with suspected microabscess in the metaphysis of the long bones can be the initial stage of the formation of Brodie's abscess and should be carefully followed up.

27 March 2021 in Skeletal Radiology
Verified
Journal Article
Open access
PDF file
SKSatoshi Kamio
Satoshi Kamio
UAUkei Anazawa
Ukei Anazawa
IWItsuo Watanabe
Itsuo Watanabe
ASAya Sasaki
Aya Sasaki
RARyoma Aoyama
Ryoma Aoyama
Methotrexate-associated lymphoproliferative disorder is recognized as a lymphoma that occurs following methotrexate administration. The lesion of the spine is extremely rare, and only one case of lesion in the lumbar spine has been reported so far. Here, we present a case of methotrexate-associated lymphoproliferative disorder of the thoracic spine in a 54-year-old woman with rheumatoid arthritis. The lesion formed an extra-skeletal tumor mass from lateral to the vertebral body to the paravertebral muscle extending posterior to the epidural space without bone destruction. Magnetic resonance imaging showed low signal intensities on both T1- and T2-weighted images and high signal intensity with short-tau inversion recovery. These radiological findings were similar to those for primary spinal lymphoma. The lesion rapidly paralyzed the patient, forcing her to be treated with posterior spinal decompression. The lesion could not be resected because it adhered to the dura. Following the histopathological diagnosis as methotrexate-associated lymphoproliferative disorder, methotrexate administration was terminated. The remaining mass lesion showed complete regression within 6 months. Methotrexate-associated lymphoproliferative disorder, which could be cured by the discontinuation of methotrexate, should be considered a differential diagnosis in spinal lesion cases showing lymphoma-like appearance with methotrexate treatment to avoid unnecessary treatments.

16 May 2024 in Human Cell
Verified
Journal Article
Closed access
PDF file
Prin SungwanPrin Sungwan
Prin Sungwan
JPJutatip Panaampon
Jutatip Panaampon
RKRyusho Kariya
Ryusho Kariya
SKSatoshi Kamio
Satoshi Kamio
RNRumi Nakagawa
Rumi Nakagawa
Seiji OkadaSeiji Okada
Seiji Okada

9 November 2025 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Closed access
SKSatoshi Kamio
Satoshi Kamio
KOKOICHI OGURA
KOICHI OGURA
YSYoshiyuki Suehara
Yoshiyuki Suehara
RKRina Kitada
Rina Kitada
MIMasachika Ikegami
Masachika Ikegami
AKAkira Kawai
Akira Kawai
Background: Ewing sarcoma (ES) is a malignant type of bone and soft tissue tumor with EWSR1–ETS gene fusions as the primary driver alteration. Incidence is higher in White populations compared to Black and Asian populations. Researchers use next-generation sequencing to identify alterations as potential therapeutic targets. We compared the data from the Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets in the USA with the data from Center for Cancer Genomics and Advanced Therapeutics in Japan. Methods: We sequenced tumor DNA from 81 ES samples using the FoundationOne® CDx for multigene panel testing. Genetic alterations were interpreted via the Cancer Knowledge Database (CKDB) and potentially actionable alterations were classified into levels A–F. Results: Analysis of 81 ES samples revealed 556 mutations in 197 genes and 126 copy-number alterations in 58 genes. Potentially actionable alterations were detected in 10 patients (12.3%) at CKDB levels A or C. STAG2 mutations accounted for 3.7%, TP53 mutations for 17.3%, and CDKN2A deletions for 13.6%. There was no significant difference in overall survival after genomic profiling test enrollment for STAG2 and TP53 mutations (P = .663 and P = .767), but those with CDKN2A and CDKN2B deletions had poor prognosis (P = .024 and P = .012). Conclusion: Compared to previous reports, Japanese ES cases showed lower STAG2 and higher TP53 mutation frequencies. CDKN2A and CDKN2B deletions may serve as prognostic biomarkers indicating unfavorable outcomes.

1 October 2025 in JBJS Open Access
Verified
Journal Article
Open access
TTToshiyuki Takemori
Toshiyuki Takemori
EKEisuke Kobayashi
Eisuke Kobayashi
AYAkihiko Yoshizawa
Akihiko Yoshizawa
AAAyumu Arakawa
Ayumu Arakawa
HKHiroya Kondo
Hiroya Kondo
KIKimiteru Ito
Kimiteru Ito
Introduction: We aimed to identify a new biomarker using 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET)/computed tomography (CT) parameters to identify osteosarcoma patients with standard response after neoadjuvant chemotherapy (NAC). Patients and Materials: Fifty-four patients with conventional osteosarcoma (age ≤39 years) were included in this study. All patients underwent 18 F-FDG PET/CT before (PET1) and after NAC (PET2). We measured PET parameters, including maximum, average, and peak standardized uptake value (SUVmax, SUVave, and SUVpeak); metabolic tumor volume (MTV); and total lesion glycolysis (TLG). Their changes (ΔPET = PET2/PET1) were also examined. The patients were classified into 4 groups based on the histological tumor necrosis rate (TNR): G0 (<50%), G1 (50 to < 90%), G2 (90 to < 100%), and G3 (100%). G0 and G1 patients were enrolled in the standard responder (SR) group (n = 35), while G2 and G3 patients were enrolled in the good responder (GR) group (n = 19). We examined the correlation between changes in each 18 F-FDG PET/CT parameter and TNR as well as overall survival (OS) and progression-free survival (PFS) among the 4 groups. In the SR group, the median value of ΔSUVmax was calculated and correlated with prognostic stratification. Results: The changes in each PET parameter were correlated with TNR, with SUVpeak showing the strongest correlation. Moreover, in the SR group, there were no differences in OS or PFS between G0 and G1. Patients in the SR group were stratified into 2 groups according to the median ΔSUVmax value (0.62). Patients with ΔSUVmax < 0.62 had significantly better OS (P < 0.01) and PFS (P = 0.02) in comparison with patients with ΔSUVmax ≥ 0.62. In multivariate analyses, ΔSUVmax showed a correlation with OS in the SR group. Discussion: This study revealed that ΔSUVmax may confirm the preoperative stratification of the prognosis be a predictive biomarker for patients in the SR group. Moreover, the preoperative identification of patients with a worse prognosis in the SR group has a significant impact on improving the clinical outcomes of patients with osteosarcoma. Level of Evidence: Prognostic studies, Level III . See Instructions for Authors for a complete description of levels of evidence.

1 April 2025 in JBJS Case Connector
Verified
Journal Article
Open access
TMTsuyoshi Mizuma
Tsuyoshi Mizuma
KYKazuki Yamamoto
Kazuki Yamamoto
KKKazutaka Kurihara
Kazutaka Kurihara
KFKeishi Furusawa
Keishi Furusawa
SKSatoshi Kamio
Satoshi Kamio
RNRobert Nakayama
Robert Nakayama
Case: Two women (aged 35 and 29 years) with intractable chronic knee infection of tumor prostheses opted for amputation. As only the trochanteric region could be preserved, we resected the remaining proximal femur and created a 15-cm long stump using unaffected proximal thigh soft tissue to avoid the drawbacks of ultra–high-thigh amputation and conventional hip disarticulation. Both had no contracture, could move their stump voluntarily, and ambulated using a standard transfemoral prosthesis without a pelvic belt at 4-year and 3-year follow-ups, respectively. Conclusion: Our procedure might benefit patients who require ultra–high-thigh amputation, with preservation of only the femoral trochanteric region.